Table 3.
Process of care measures and clinical outcomes of HF QUIK participants by control and intervention period.
| Control (n=758) | Intervention (n=642) | Difference (95% CI)1 | |||
|---|---|---|---|---|---|
| N | n (%) | N | n (%) | ||
| Discharge process of care measures2 | |||||
| GDMT at discharge3 | 440 | 124 (28.2) | 404 | 167 (41.3) | 13.2 (6.8, 19.5) |
| ACE-I or ARB at discharge3 | 440 | 200 (45.5) | 403 | 207 (51.4) | 5.9 (−0.8, 12.7) |
| Beta-blocker at discharge3 | 440 | 333 (75.7) | 404 | 332 (82.2) | 6.5 (1.0, 12.0) |
| Aldosterone antagonist at discharge3 | 440 | 286 (65.0) | 404 | 305 (75.5) | 10.5 (4.4, 16.6) |
| Diuretic at discharge3 | 440 | 411 (93.4) | 404 | 397 (98.3) | 4.9 (2.2, 7.5) |
| Tobacco cessation counseling4 | 420 | 266 (63.3) | 355 | 229 (64.5) | 1.2 (−5.6, 8.0) |
| Alcohol cessation counseling4 | 407 | 246 (60.4) | 343 | 213 (62.1) | 1.7 (−5.3, 8.7) |
| Diet counseling | 689 | 589 (85.5) | 587 | 510 (86.9) | 1.4 (−2.4, 5.2) |
| Weight monitoring instructions | 689 | 576 (83.6) | 587 | 507 (86.4) | 2.8 (−1.2, 6.7) |
| Referral to outpatient cardiac rehabilitation | 690 | 30 (4.3) | 586 | 16 (2.7) | −1.6 (−3.6, 0.4) |
| Referral for ICD therapy5 | 364 | 20 (5.5) | 322 | 8 (2.5) | −3.0 (−5.9, −0.1) |
| Outpatient clinic follow-up scheduled | 690 | 618 (89.6) | 587 | 565 (96.3) | 6.7 (3.9, 9.4) |
| In-hospital process of care measures | |||||
| ECG | 758 | 751 (99.1) | 642 | 641 (99.8) | 0.8 (0.02, 1.5) |
| Transthoracic echocardiogram | 757 | 710 (93.8) | 642 | 591 (92.1) | −1.7 (−4.4, 1.0) |
| Clinical outcomes | |||||
| Hospital length of stay, median (IQR), days | 756 | 4 (3–6) | 641 | 4 (3–6) | 0.0 (−0.3, 0.3) |
| Inpatient mortality | 756 | 66 (8.7) | 642 | 55 (8.6) | −0.2 (−3.1, 2.8) |
Crude difference: Intervention minus control calculated either as a risk difference percentage for count data or difference in medians for continuous nonparametric data.
Among participants discharged; N = 1279 with 692 in control period and 587 in intervention period
Among participants discharged with LVEF <40%; N = 846 with 442 in control period and 404 in intervention period
Among participants who reported tobacco or alcohol use; N = 775 and N = 750 for tobacco and alcohol use respectively
Among participants with LVEF ≤35%; N = 688 with 366 in control period and 322 in intervention period
ACE-I: angiotensin converting enzyme inhibitor, ARB: angiotensin receptor blocker, GDMT: guideline-directed medical therapy, ICD: implantable cardioverter defibrillator, LVEF: center ventricular ejection fraction, ECG: electrocardiogram